Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 9/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSH | P09668 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799663 | 0.81 | ALDH1A1 (0.53) | NPC1RAB9AALDH1A1S1PR4MAPT | |
| SCHEMBL10025751 | 0.78 | NPC1 (0.51) | NPC1RAB9AALDH1A1S1PR4MAPT | |
| SCHEMBL187124 | 0.78 | CTSB (0.56) | NPC1RAB9AALDH1A1S1PR4MAPT | |
| SCHEMBL31121580 | 0.78 | CTSB (0.56) | NPC1RAB9AALDH1A1S1PR4MAPT | |
| SCHEMBL28051995 | 0.78 | S1PR4 (0.52) | NPC1RAB9AALDH1A1S1PR4MAPT | |
| SCHEMBL5149307 | 0.75 | MAPT (0.34) | NPC1RAB9AALDH1A1S1PR4MAPT | |
| SCHEMBL187354 | 0.75 | NPC1 (0.64) | NPC1RAB9AALDH1A1S1PR4MAPT | |
| SCHEMBL6785310 | 0.75 | ALDH1A1 (0.46) | NPC1RAB9AALDH1A1S1PR4MAPT | |
| SCHEMBL2475369 | 0.73 | ALDH1A1 (0.47) | NPC1RAB9AALDH1A1S1PR4MAPT | |
| SCHEMBL8790468 | 0.73 | NPC1 (0.57) | NPC1RAB9AALDH1A1S1PR4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4831966-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | claimed |
| CN-1305871-C | For the treatment of 5-HT2APiperazinyl-pyrazinone derivatives for receptor related diseases | BIOVITRUM AB (SE) | 2007-03-21 | — | — | CN | claimed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | claimed |
| CN-1675198-A | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2a receptor-related disorders | BIOVITRUM AB (SE) | 2005-09-28 | — | — | CN | claimed |
| EP-1534391-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | Biovitrum AB (SE) | 2005-06-01 | — | — | EP | claimed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | claimed |
| WO-2004009586-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2004-01-29 | — | — | WO | claimed |
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | disclosed |
| CN-1305871-C | For the treatment of 5-HT2APiperazinyl-pyrazinone derivatives for receptor related diseases | BIOVITRUM AB (SE) | 2007-03-21 | — | — | CN | disclosed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| CN-1675198-A | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2a receptor-related disorders | BIOVITRUM AB (SE) | 2005-09-28 | — | — | CN | disclosed |
| EP-1534391-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | Biovitrum AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | disclosed |
| WO-2004009586-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063693-A1 | Compounds | HTR1A, HTR1B, HTR2C | NPC1 522/4885RAB9A 1468/4885ALDH1A1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.